Comparison of 2 Free Light Chain Assays: Performance of the Free Light Chain Ratio as a Risk Factor for MGUS Progression
The Sebia ELISA-based FLC assay can be employed in an MGUS risk stratification model with similar performance to the original 2005 risk stratification model using the FreeLite assay.
Authors
- Angela A. Dispenzieri (ORCID: https://orcid.org/0000-0001-8780-9512)
- Benjamin Andress (ORCID: https://orcid.org/0000-0001-6562-4832)
- Dirk R. Larson (ORCID: https://orcid.org/0000-0002-2970-2124)
- Maria Alice V. Willrich (ORCID: https://orcid.org/0000-0002-9318-7091)
- David Murray (ORCID: https://orcid.org/0000-0003-1720-335X)
- Surendra Dasari (ORCID: https://orcid.org/0000-0002-7972-3556)
- S. Vincent Rajkumar (ORCID: https://orcid.org/0000-0002-5862-1833)
- Vanessa Pazdernik (ORCID: https://orcid.org/0000-0001-7566-7334)
- Qian Wang (ORCID: https://orcid.org/0009-0008-8647-6347)
- Jonathan Coker
Institutions
- Mayo Clinic (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Clinical Chemistry
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1093/clinchem/hvae124
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.45